Half-Year Report — FY2026 H1
What ReproCELL Incorporated reported for the period from 2026-04-01 to 2027-03-31.
Filed 2026-11-12View the original on EDINET
How much it says
49Typical
What moved here
41named for the first time
Its own wording
48terms
Which filing this is
34/ 34newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the current interim consolidated accounting period (1 April 2026 to 30 September 2026), revenue was ¥1,156 million, operating loss was ¥497 million, and interim net loss attributable to owners of the parent was ¥319 million. In addition, the Company’s share capital and capital surplus increased as a result of a third-party allotment of shares and share acquisition rights by CVI Investments, Inc.
Komori's summary of this document, not the document's own words.49Typical
How much this filing saysA weighted roll-up of 12 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 38 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
80
Very detailed
54
Typical
82
Very detailed
62
Detailed
0
Almost nothing
0
Almost nothing
53
Typical
55
Typical
31
Thin
60
Detailed
55
Typical
50
Typical
R&D spend4億円Money spent making new things.
Cash left over-9億円Cash from the business, less what went into equipment.
Spent on equipment12百万円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.